Interleukin-6-type cytokines in myeloproliferative disease.
Hawley
R G
RG
Division of Cancer Biology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
D002455:Cell Division; D015972:Gene Expression Regulation, Neoplastic; D011905:Genes, ras; D006131:Growth Inhibitors / Q000502:physiology*; D006410:Hematopoiesis; D006801:Humans; D017370:Interleukin-11 / Q000502:physiology*; D015850:Interleukin-6 / Q000502:physiology*; D053605:Leukemia Inhibitory Factor; D015470:Leukemia, Myeloid, Acute / Q000503:physiopathology*; D008222:Lymphokines / Q000502:physiology*; D009190:Myelodysplastic Syndromes / Q000503:physiopathology*; D009196:Myeloproliferative Disorders / Q000503:physiopathology*; D053683:Oncostatin M; D010455:Peptides / Q000502:physiology*; D011828:Radiation Chimera; D014407:Tumor Cells, Cultured
D006131:Growth Inhibitors; D017370:Interleukin-11; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; C508351:OSM protein, human; D010455:Peptides; D053683:Oncostatin M